Koru Medical reports Q1 EPS (3c), consensus (3c)

Reports Q1 revenue $9.6M, consensus $8.9M. “We are off to a strong start this year, with over 20% growth in our core business driven by new patient starts and continued market share gains both domestically and internationally, all contributing to the expansion of our recurring revenue base,” said Linda Tharby, President and CEO of KORU Medical (KRMD). “We are also advancing our novel therapies pipeline and announcing plans to submit two previously commercialized drugs for 510(k) clearance with the Freedom Infusion system by year-end. Despite a challenging macroeconomic backdrop, the positive momentum in our business gives us confidence in our ability to deliver through the remainder of the year, and we are raising our full-year revenue guidance accordingly.”